Global CAR T-Cell Therapy Market Analysis 2019

Tutorials Get 15% Discount on First Report

The CAR T-Cell Therapy market is expected to reach $13,617.10 million by 2026 growing at a CAGR of 56.2% from 2018 to 2026. Chimeric Antigen Receptor (CAR) T Cell Therapy is a type of treatment in which patient T cells are changed in the laboratory to attack the cancer cells. In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient’s cancer cells. CAR T-cell therapy uses patients own modified white blood cells to kill the cancer cells. CAR T-cell therapy is moreover a living drug and its benefits can last for many years. CAR T cell therapy is used in curing patients with breast cancer, pancreas cancer, colorectal cancer and various types of blood cancer.

Factors such as technological advancement for advanced & reliable treatment for cancer, growing pharmaceutical industry, high prevalence of acute lymphoblastic lymphoma (ALL) and increase in the number of cell therapy clinical studies are fuelling the market growth. However, side-effects of CAR T-cell therapy and high cost of treatment are likely to hamper the market growth.

Based on the application, diffuse large B-cell lymphoma is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults. This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age, though it can also occur in children and young adults in rare cases. DLBCL is an aggressive tumour which can arise in virtually any part of the body, and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with B symptoms of fever, weight loss, and night sweats.

The key vendors mentioned are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc., Pfizer, Inc., Juno Therapeutics, Atara Biotherapeutics, Aurora Biopharma Inc., Eureka Therapeutics, Autolus, TILT Biotherapeutics, and Fortress Biotech.

Target Antigens Covered:
• CD20
• EGFRV III
• CD19
• HER2
• MESO
• CD22
• BCMA
• GD2
• CD30
• HER1
• CD33

Products Covered:
• Allogeneic
• Autologous

Therapies Covered:
• Axicabtagene Ciloleucel (Yescarta)
• Tisagenlecleucel (Kymriah)

Applications Covered:
• Chronic Lymphocytic Leukemia
• Diffuse Large B-Cell Lymphoma
• Multiple Myeloma
• Acute Lymphoblastic Leukemia
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Glioblastoma
• Neuroblastoma
• Breast Cancer
• Sarcoma
• Acute Myeloid Leukemia
• Colorectal Cancer
• Pancreatic Cancer
• Hepatocellular Carcinoma
• Non-Hodgkin Leukemia
• Carcinoma

End Users Covered:
• Cancer Research Centers
• Hospitals
• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations

Regions Covered:
• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Key Questions Answered in this Report:
• How this market evolved since the year 2016
• Market size estimations, forecasts and CAGR for all the segments presented in the scope
• Key Market Developments and financials of the key players
• Opportunity Analysis for the new entrants
• SWOT Analysis of the key players
• Fastest growing markets analysed during the forecast period

Your Name:
Your Phone:
Company Name:
Country:
Your Email:
Description:

1 Market Synopsis

2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources

3 Market Dynamics
3.1 Drivers
3.2 Restraints

4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global CAR T-Cell Therapy Market, By Target Antigen
5.1 Introduction
5.2 CD20
5.3 EGFRV III
5.4 CD19
5.5 HER2
5.6 MESO
5.7 CD22
5.8 BCMA
5.9 GD2
5.10 CD30
5.11 HER1
5.12 CD33

6 Global CAR T-Cell Therapy Market, By Product
6.1 Introduction
6.2 Allogeneic
6.3 Autologous

7 Global CAR T-Cell Therapy Market, By Therapy
7.1 Introduction
7.2 Axicabtagene Ciloleucel (Yescarta)
7.3 Tisagenlecleucel (Kymriah)

8 Global CAR T-Cell Therapy Market, By Application
8.1 Introduction
8.2 Chronic Lymphocytic Leukemia
8.3 Diffuse Large B-Cell Lymphoma
8.4 Multiple Myeloma
8.5 Acute Lymphoblastic Leukemia
8.6 Follicular Lymphoma
8.7 Mantle Cell Lymphoma
8.8 Glioblastoma
8.9 Neuroblastoma
8.10 Breast Cancer
8.11 Sarcoma
8.12 Acute Myeloid Leukemia
8.13 Colorectal Cancer
8.14 Pancreatic Cancer
8.15 Hepatocellular Carcinoma
8.16 Non-Hodgkin Leukemia
8.17 Carcinoma

9 Global CAR T-Cell Therapy Market, By End User
9.1 Introduction
9.2 Cancer Research Centers
9.3 Hospitals
9.4 Academic and Research Institutes
9.5 Pharmaceutical Companies
9.6 Biotechnology Companies
9.7 Contract Research Organizations

10 Global CAR T-Cell Therapy Market, By Geography
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 South America
10.5 Middle East & Africa

11 Strategic Benchmarking

12 Vendors Landscape
12.1 Mustang Bio, Inc.
12.2 Celgene Corporation
12.3 Bluebird Bio, Inc.
12.4 CARsgen Therapeutics, Ltd.
12.5 Novartis International AG
12.6 Legend Biotech
12.7 Sorrento Therapeutics Inc.
12.8 Kite Pharma, Inc.
12.9 Immune Therapeutics
12.10 Bellicum Pharmaceuticals, Inc.
12.11 Pfizer, Inc.
12.12 Juno Therapeutics
12.13 Atara Biotherapeutics
12.14 Aurora Biopharma Inc.
12.15 Eureka Therapeutics
12.16 Autolus
12.17 TILT Biotherapeutics
12.18 Fortress Biotech

List of Data Tables
1 Global CAR T-Cell Therapy Market Outlook, By Region (2016-2026) ($MN)
2 Global CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
3 Global CAR T-Cell Therapy Market Outlook, By CD20 (2016-2026) ($MN)
4 Global CAR T-Cell Therapy Market Outlook, By EGFRV III (2016-2026) ($MN)
5 Global CAR T-Cell Therapy Market Outlook, By CD19 (2016-2026) ($MN)
6 Global CAR T-Cell Therapy Market Outlook, By HER2 (2016-2026) ($MN)
7 Global CAR T-Cell Therapy Market Outlook, By MESO (2016-2026) ($MN)
8 Global CAR T-Cell Therapy Market Outlook, By CD22 (2016-2026) ($MN)
9 Global CAR T-Cell Therapy Market Outlook, By BCMA (2016-2026) ($MN)
10 Global CAR T-Cell Therapy Market Outlook, By GD2 (2016-2026) ($MN)
11 Global CAR T-Cell Therapy Market Outlook, By CD30 (2016-2026) ($MN)
12 Global CAR T-Cell Therapy Market Outlook, By HER1 (2016-2026) ($MN)
13 Global CAR T-Cell Therapy Market Outlook, By CD33 (2016-2026) ($MN)
14 Global CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
15 Global CAR T-Cell Therapy Market Outlook, By Allogeneic (2016-2026) ($MN)
16 Global CAR T-Cell Therapy Market Outlook, By Autologous (2016-2026) ($MN)
17 Global CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
18 Global CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (Yescarta) (2016-2026) ($MN)
19 Global CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (Kymriah) (2016-2026) ($MN)
20 Global CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
21 Global CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2016-2026) ($MN)
22 Global CAR T-Cell Therapy Market Outlook, By Diffuse Large B-Cell Lymphoma (2016-2026) ($MN)
23 Global CAR T-Cell Therapy Market Outlook, By Multiple Myeloma (2016-2026) ($MN)
24 Global CAR T-Cell Therapy Market Outlook, By Acute Lymphoblastic Leukemia (2016-2026) ($MN)
25 Global CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2016-2026) ($MN)
26 Global CAR T-Cell Therapy Market Outlook, By Mantle Cell Lymphoma (2016-2026) ($MN)
27 Global CAR T-Cell Therapy Market Outlook, By Glioblastoma (2016-2026) ($MN)
28 Global CAR T-Cell Therapy Market Outlook, By Neuroblastoma (2016-2026) ($MN)
29 Global CAR T-Cell Therapy Market Outlook, By Breast Cancer (2016-2026) ($MN)
30 Global CAR T-Cell Therapy Market Outlook, By Sarcoma (2016-2026) ($MN)
31 Global CAR T-Cell Therapy Market Outlook, By Acute Myeloid Leukemia (2016-2026) ($MN)
32 Global CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2016-2026) ($MN)
33 Global CAR T-Cell Therapy Market Outlook, By Pancreatic Cancer (2016-2026) ($MN)
34 Global CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2016-2026) ($MN)
35 Global CAR T-Cell Therapy Market Outlook, By Non-Hodgkin Leukemia (2016-2026) ($MN)
36 Global CAR T-Cell Therapy Market Outlook, By Carcinoma (2016-2026) ($MN)
37 Global CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)
38 Global CAR T-Cell Therapy Market Outlook, By Cancer Research Centers (2016-2026) ($MN)
39 Global CAR T-Cell Therapy Market Outlook, By Hospitals (2016-2026) ($MN)
40 Global CAR T-Cell Therapy Market Outlook, By Academic and Research Institutes (2016-2026) ($MN)
41 Global CAR T-Cell Therapy Market Outlook, By Pharmaceutical Companies (2016-2026) ($MN)
42 Global CAR T-Cell Therapy Market Outlook, By Biotechnology Companies (2016-2026) ($MN)
43 Global CAR T-Cell Therapy Market Outlook, By Contract Research Organizations (2016-2026) ($MN)
44 North America CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
45 North America CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
46 North America CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
47 North America CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
48 North America CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)
49 Europe CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
50 Europe CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
51 Europe CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
52 Europe CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
53 Europe CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)
54 Asia Pacific CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
55 Asia Pacific CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
56 Asia Pacific CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
57 Asia Pacific CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
58 Asia Pacific CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)
59 South America CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
60 South America CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
61 South America CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
62 South America CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
63 South America CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)
64 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
65 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
66 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
67 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
68 Middle East & Africa CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)

Your Name:
Your Phone:
Company Name:
Country:
Your Email:
Description:

Related Reports

Global Biomedical Sensor Market Analysis 2020

May, 2020

Biomedical sensors are the tools used for the detection of a specific chemical, physical or biological process and then transmit...

Global Transfection Technologies Market Analysis 2020

May, 2020

Transfection is an approach adopted for the production of exogenous nucleic acids into the cells....

Global Biomarkers Market Analysis 2020

May, 2020

Biomarkers are used in imaging technology to provide clear imaging of oncology tumors and additional problems....

Global Smart Pills Capusule Endoscopy Market Analysis 2020

May, 2020

Smart Pill is an ingestible capsule that estimates pressure, pH and temperature as it travels through the gastrointestinal (GI) tract...